Yutrepia Capsule
NDC Package 72964-014-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Yutrepia (treprostinil) capsules is a medication used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). This formulation utilizes a capsule delivery system. Marketed by Liquidia Technologies, Inc., this product is identified by NDC 72964-014 and is authorized under FDA application NDA213005.

Identification & Billing

NDC Package Code
72964-014-01
Package Description
7 BLISTER PACK in 1 CARTON / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULE
Product Code
72964-014
11-Digit Billing Format
72964001401
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
7 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Yutrepia
Non-Proprietary Name
Treprostinil
Substance Name
Treprostinil Sodium
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Active Ingredient(s)
TREPROSTINIL SODIUM 106 ug/1
Pharmacologic Class
Usage Information
This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to increase your ability to exercise and improves symptoms such as shortness of breath and tiredness. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

Regulatory & Marketing

Labeler Name
Liquidia Technologies, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA213005
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-23-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72964-014-01 identifies a specific commercial package of 7 blister pack in 1 carton / 4 capsule in 1 blister pack / 1 capsule in 1 capsule of Yutrepia, a human prescription drug labeled by Liquidia Technologies, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 7 billable units per package. This capsule is formulated for respiratory (inhalation) use and contains treprostinil sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Liquidia Technologies, Inc. on May 23, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to increase your ability to exercise and improves symptoms such as shortness of breath and tiredness. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

How is this Liquidia Technologies, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72964001401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 7 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72964-014-01
11-Digit CMS (5-4-2)
72964-0014-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.